Modalis Therapeutics (TSE:4883) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Modalis Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was 円0.00 Mil. Modalis Therapeutics's Revenue for the three months ended in Dec. 2024 was 円0.00 Mil. Therefore, Modalis Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Modalis Therapeutics's current FCF Yield % is -25.63%.

The historical rank and industry rank for Modalis Therapeutics's FCF Margin % or its related term are showing as below:

During the past 7 years, the highest FCF Margin % of Modalis Therapeutics was 26.36%. The lowest was -77688.82%. And the median was -352.80%.

TSE:4883's FCF Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.87
* Ranked among companies with meaningful FCF Margin % only.

Modalis Therapeutics FCF Margin % Historical Data

The historical data trend for Modalis Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics FCF Margin % Chart

Modalis Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-352.80

-77,688.82

-5,168.05

Modalis Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Modalis Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Modalis Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Modalis Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Modalis Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Modalis Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-1432.193	/	0
	=	%

Modalis Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0
	=	%

Modalis Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Modalis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026

Website

https://www.modalistx.com

Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics Headlines

No Headlines